- Results of a meta-analysis based on real-world evidence suggest a protective effect of thiazolidinediones (TZDs) against Parkinson disease (PD), particularly in people with type 2 diabetes (T2D).
Why this matters
- Currently, no disease-modifying treatment prevents PD or slows its progression.
- TZDs suppress neuroinflammatory processes in microglia and astrocytes, but evidence of a neuroprotective effect in humans has been inconsistent.
- Meta-analysis of 4 retrospective cohort studies with 312,924 participants with T2D, including 66,129 TZD users.
- Also used data for nonusers of TZDs from another retrospective study, pooled for the secondary outcome of PD risk among TZD users with T2D vs a general population of nonusers.
- Funding: None disclosed.
- Pooled adjusted (a)HR for PD among people with T2D who used vs did not use TZDs was 0.81 (P=.004).
- The protective effect was significant for a subgroup with >5 years of follow-up (aHR, 0.74; P=.0008) but not with ≤5 years (aHR, 0.95; P=.68).
- The effect was significant for white populations (aHR, 0.78; P=.003) but not among people of Asian ancestry (aHR, 0.90; P=.45).
- The protective effect was also significant for TZD users vs nonusers, including people without T2D (aHR, 0.72; P=.04).
- Included only English-language articles.
- All included studies were retrospective.